Related Experiment Video
Updated: Sep 8, 2025

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
Old age and multiple comorbidity are associated with delayed diagnosis of Guillain-Barre syndrome
Sohyeon Kim1, Hee Jo Han1, Ha Young Shin1
1Department of Neurology, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
Insights
Older age and multiple comorbidities, including malignancy and cardiovascular diseases, are linked to delayed Guillain-Barré syndrome (GBS) diagnosis. Early GBS suspicion is crucial for these high-risk patients.
Area of Science:
- Neurology
- Clinical Medicine
- Epidemiology
Background:
- Guillain-Barré syndrome (GBS) diagnosis can be challenging.
- Factors influencing diagnostic delay in GBS require further investigation.
Purpose of the Study:
- To determine if older age and comorbidities are associated with delayed Guillain-Barré syndrome diagnosis.
- To identify specific comorbidities that may prolong the time to GBS diagnosis.
Main Methods:
- Retrospective review of 140 Guillain-Barré syndrome patient records (March 2011-December 2020).
- Assessment of comorbidity profiles using the Charlson Comorbidity Index (CCI) and age-adjusted CCI (ACCI).
- Classification of patients into early (≤14 days) and late (>14 days) diagnosis groups for comparative analysis.
Main Results:
- Late diagnosis group showed significantly higher age (61.8 vs. 49.1 years) and CCI scores (26.1% vs. 5.1% with CCI ≥3).
- Age-adjusted CCI score positively correlated with diagnosis duration (p < 0.001).
- Diagnosis duration was significantly longer in patients with higher ACCI scores and specifically in those with malignancy and cardiovascular diseases.
Conclusions:
- Delayed diagnosis of Guillain-Barré syndrome is associated with older age and a higher burden of comorbidities.
- Malignancy and cardiovascular diseases are key comorbidities contributing to diagnostic delays in GBS.
- Increased clinical suspicion for GBS is warranted in elderly patients and those with significant comorbidities, particularly cancer and heart disease.
Abstract:
To assess whether older age and presence of comorbidities were associated with a delayed diagnosis of Guillain-Barré syndrome (GBS). The medical records of 140 patients diagnosed with GBS at Severance Hospital from March 2011 to December 2020 were retrospectively reviewed. Comorbidity profiles were assessed using the Charlson comorbidity index (CCI). The age-adjusted CCI (ACCI) score was calculated, which further incorporated the effect of age. Patients were classified into the early diagnosis group (diagnosis duration ≤ 14 days) and late diagnosis group (diagnosis duration > 14 days). Clinical features and comorbidity profiles were compared between the two groups. The cumulative incidence of diagnosis was compared between the low and high ACCI groups. Age was significantly higher in the late diagnosis group (61.8 ± 15.0 years) than in the early diagnosis group (49.1 ± 18.4, p = 0.001). The CCI score was higher in the late diagnosis group (≥ 3 in 26.1%) than in the early diagnosis group (≥ 3 in 5.1%, p = 0.01). The ACCI score demonstrated a positive correlation with the diagnosis duration (β = 1.636, p < 0.001), indicating that the diagnosis was delayed in patients with a higher ACCI score. The duration from onset to diagnosis was longer in the high ACCI group than in the low ACCI group (log-rank test, p < 0.001). The diagnosis duration was significantly longer, especially in patients with malignancy and cardiovascular diseases. Delayed diagnosis of GBS is associated with older age and multiple comorbidities. Diagnostic delay was significant in patients with malignancies and cardiovascular diseases. Early suspicion of GBS is required in these patients.
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

